Abstract: The present invention relates to a method of culturing mesenchymal stem cells using gamma-irradiated serum, and more particularly to a method for culturing mesenchymal stem cells, which can improve the adhesion and proliferation rate of stem cells using a medium containing gamma-irradiated serum and an antioxidant. The method for culturing mesenchymal stem cells according to the present invention can restore the adhesion and proliferation rate of stem cells when culturing the stem cells using gamma-irradiated FBS, which is safe from contamination sources but reduces the efficiency of adhesion and proliferation of the cells. Thus, the inventive method is useful for the production of stem cells for cell therapy.

Abstract: The present invention relates to a method for preparing stem cells having a size suitable for intravascular administration, and preferably to a method for preparing stem cells with a diameter ranging from 11-16 ?m. Additionally, the present invention relates to media composition for preparing stem cells having a size suitable for intravascular administration. According to the present invention, stem cells having a size suitable for intravascular administration can be prepared such that stem cells administered into a vein can stably reach a target tissue, and thus can more efficiently increase efficacy displaying activity, thereby innovatively enhancing the efficacy of cell therapy using stem cells.

Abstract: The present invention relates to a method for preparing stem cells having a size suitable for intravascular administration, and preferably to a method for preparing stem cells with a diameter ranging from 11-16 ?m. Additionally, the present invention relates to media composition for preparing stem cells having a size suitable for intravascular administration. According to the present invention, stem cells having a size suitable for intravascular administration can be prepared such that stem cells administered into a vein can stably reach a target tissue, and thus can more efficiently increase efficacy displaying activity, thereby innovatively enhancing the efficacy of cell therapy using stem cells.

Abstract: The present invention relates to a method of culturing mesenchymal stem cells using gamma-irradiated serum, and more particularly to a method for culturing mesenchymal stem cells, which can improve the adhesion and proliferation rate of stem cells using a medium containing gamma-irradiated serum and an antioxidant. The method for culturing mesenchymal stem cells according to the present invention can restore the adhesion and proliferation rate of stem cells when culturing the stem cells using gamma-irradiated FBS, which is safe from contamination sources but reduces the efficiency of adhesion and proliferation of the cells. Thus, the inventive method is useful for the production of stem cells for cell therapy.

Abstract: The present disclosure relates to a medium composition for culturing stem cells, and more specifically, to a medium composition for culturing mesenchymal stem cells, in which the medium composition includes a basic medium in which various quasi-completed mediums (DMEM, ?-MEM, IMDM, F12, and DMEM/F12) are mixed, L-ascorbic acid 2-phosphate, fetal bovine serum, basic fibroblast growth factors (b-FGF), insulin, N-acetyl-L-cysteine, calcium chloride, and hydrocortisone. According to the present disclosure, it is capable of improving proliferation ability and differentiation ability of the mesenchymal stem cells, and is capable of producing cell therapy products more economically using the mesenchymal stem cells by enabling the mesenchymal stem cells to be cultured at a low price compared to the existing culturing methods.

Abstract: The present invention relates to a medium composition for enhancing the self-renewal ability of stem cells, which contains apelin, and a method of culturing stem cells using the medium composition. According to the present invention, stem cells can be effectively cultured to proliferate without changing the characteristics of the cells, and the telomerase activity of stem cells can be increased. Thus, the efficacy of cell therapy based on stem cells can be significantly improved.

Abstract: The present disclosure relates to a medium composition for culturing stem cells, and more specifically, to a medium composition for culturing mesenchymal stem cells, in which the medium composition includes a basic medium in which various quasi-completed mediums (DMEM, ?-MEM, IMDM, F12, and DMEM/F12) are mixed, L-ascorbic acid 2-phosphate, fetal bovine serum, basic fibroblast growth factors (b-FGF), insulin, N-acetyl-L-cysteine, calcium chloride, and hydrocortisone. According to the present disclosure, it is capable of improving proliferation ability and differentiation ability of the mesenchymal stem cells, and is capable of producing cell therapy products more economically using the mesenchymal stem cells by enabling the mesenchymal stem cells to be cultured at a low price compared to the existing culturing methods.

Abstract: The present invention relates to a medium composition for transforming stem cells from an aged person into young stem cells, and more particularly to a medium composition for culturing stem cells, which is used to rejuvenate stem cells from an aged person so as to have characteristics similar to those of the stem cells of young people, and to a method for rejuvenating stem cells, which comprises culturing stem cells from an aged person in the medium composition. According to the present invention, even mesenchymal stem cells collected from over 60 years old patients can be transformed into young mesenchymal stem cells having high differentiation ability, high telomerase activity, and high ability to express stem cell markers. Thus, the present invention can significantly increase the efficacy of cell therapy employing mesenchymal stem cells.

Abstract: An embryonic stem cell line derived from a nucleus-transferred oocyte prepared by transferring a nucleus of a human somatic cell into an enucleated human oocyte may differentiate into various desired cell types.

Abstract: There is provided a method for preventing disruption and aggregation of stem cells. In addition, there is provided a stem cell composition for intravascular administration, in which stem cells are suspended in a solution containing aspirin. Further, there is provided a composition for preventing disruption or aggregation of stem cells, in which stem cells are suspended in a solution containing aspirin. According to the present invention, disruption and aggregation of cells may be prevented during transport or storage, such that the administered stem cells may stably reach the target tissue and exhibit the activity thereof in a more efficient manner, thereby remarkably increasing the effect of cell therapy using stem cells.

Abstract: The present invention relates to a medium composition for enhancing the self-renewal ability of stem cells, which contains apelin, and a method of culturing stem cells using the medium composition. According to the present invention, stem cells can be effectively cultured to proliferate without changing the characteristics of the cells, and the telomerase activity of stem cells can be increased. Thus, the efficacy of cell therapy based on stem cells can be significantly improved.

Abstract: The present invention relates to a stem cell composition for intravenous administration, which contains stem cells at a concentration of 1×107 to 5×108 cells/ml, in which the stem cells have a diameter of 10-20 ?m and are present as single cells. The stem cell composition according to the present invention is suitable for intravenous administration, and enables the stem cells to securely reach a target tissue after intravascular administration so as to exhibit their activity in the target tissue. Thus, it can significantly increase the therapeutic effects of the stem cells.

Abstract: The present invention relates to a method for preparing stem cells in high concentration. The present invention makes it possible to grow stem cells in an amount sufficient to be clinically usable in a short time, and makes it possible to relatively efficiently enhance the ability of administered stem cells to efficaciously reach target tissue and exhibit an action in a stable fashion and can therefore dramatically increase the efficacy of cell therapy using stem cells.

Abstract: There is provided a method for preventing disruption and aggregation of stem cells. In addition, there is provided a stem cell composition for intravascular administration, in which stem cells are suspended in a solution containing aspirin. Further, there is provided a composition for preventing disruption or aggregation of stem cells, in which stem cells are suspended in a solution containing aspirin. According to the present invention, disruption and aggregation of cells may be prevented during transport or storage, such that the administered stem cells may stably reach the target tissue and exhibit the activity thereof in a more efficient manner, thereby remarkably increasing the effect of cell therapy using stem cells.

Abstract: The present invention relates to a method for preparing stem cells having a size suitable for intravascular administration, and preferably to a method for preparing stem cells with a diameter ranging from 11-16 ?m. Additionally, the present invention relates to media composition for preparing stem cells having a size suitable for intravascular administration. According to the present invention, stem cells having a size suitable for intravascular administration can be prepared such that stem cells administered into a vein can stably reach a target tissue, and thus can more efficiently increase efficacy displaying activity, thereby innovatively enhancing the efficacy of cell therapy using stem cells.

Abstract: The present invention relates to a medium composition for transforming stem cells from an aged person into young stem cells, and more particularly to a medium composition for culturing stem cells, which is used to rejuvenate stem cells from an aged person so as to have characteristics similar to those of the stem cells of young people, and to a method for rejuvenating stem cells, which comprises culturing stem cells from an aged person in the medium composition. According to the present invention, even mesenchymal stem cells collected from over 60 years old patients can be transformed into young mesenchymal stem cells having high differentiation ability, high telomerase activity, and high ability to express stem cell markers. Thus, the present invention can significantly increase the efficacy of cell therapy employing mesenchymal stem cells.

Abstract: The present invention relates to a medium for culturing mesenchymal stem cells, and more particularly to a medium composition for culturing mesenchymal stem cells, which contains basal medium, L-ascorbic acid 2-phosphate, fetal bovine serum, basic fibroblast growth factor (b-FGF), non-essential amino acids (NEAAs), insulin, N-acetyl-L-cysteine, calcium chloride, and hydrocortisone, and a method of culturing mesenchymal stem cells using the same. According to the present invention, a number of mesenchymal stem cells required for stem cell therapy can be obtained in a short time, and the ability of mesenchymal stem cells to differentiate is improved so that they are useful for stem cell therapy.

Abstract: The present invention relates to the ability of adipose tissue-derived adult stem cells to migrate, and more particularly to the novel use of adipose tissue-derived adult stem cells primed with a specific chemokine or growth factor and their specific secretory products, which more effectively migrate to a disease site in vivo. The inventive composition containing either adipose-derived adult stem cells or adipose tissue-derived adult stem cells primed with a specific chemokine or growth factor can be administered by a simple method such as intravenous administration and are able to induce the targeting of the stem cells to a disease site. Thus, the composition is useful as a cell therapeutic agent.

Abstract: An embryonic stem cell line derived from a nucleus-transferred oocyte prepared by transferring a nucleus of a human somatic cell into an enucleated human oocyte may differentiate into various desired cell types.

Abstract: An embryonic stem cell line derived from a nucleus-transferred oocyte prepared by transferring a nucleus of a human somatic cell into an enucleated human oocyte may differentiate into various desired cell types.